BioXcel Therapeutics (BTAI) - News Mentions

Sign up to add (BTAI) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 2 33.3%
Gilead Sciences
Gilead Sciences
GILD		 2 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 1 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
September 10
HC Wainwright Reaffirms Buy Rating for BioXcel Therapeutics (NASDAQ:BTAI)
August 29
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
August 27
BioXcel Therapeutics announces SERENITY Phase 3 trial met primary endpoint
August 27
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
August 26
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
August 26
BioXcel Therapeutics completes database lock for SERENITY Phase 3 trial
August 19
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
August 19
BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On?
August 18
BioXcel Therapeutics announces pre-sNDA meeting responses from FDA
August 18
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
August 18
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Rating of “Moderate Buy” from Analysts
August 18
HC Wainwright Forecasts Strong Price Appreciation for BioXcel Therapeutics (NASDAQ:BTAI) Stock
August 17
BioXcel Therapeutics (NASDAQ:BTAI) Price Target Raised to $10.00
August 17
BioXcel Therapeutics’ (BTAI) “Buy” Rating Reiterated at HC Wainwright
August 17
BioXcel Therapeutics price target raised by $2 at H.C. Wainwright, here's why
August 15

How often is BioXcel Therapeutics mentioned in the news?

BioXcel Therapeutics was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is BioXcel Therapeutics performing compared to its industry peers?

BioXcel Therapeutics underperforms its industry peers when it comes to News Mentions, ranking dead last.

Why is it important to track news mentions for BioXcel Therapeutics?

By monitoring mentions in the news for BioXcel Therapeutics, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of BioXcel Therapeutics, ultimately improving their investment strategies.

Sign up and get more insights on BioXcel Therapeutics.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
House & Congress Trading
Earnings Calendar
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Top Stocks
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
You need to log in to use AltIndex AI Chat.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.